The XE-2100 hematology analyzer, recently cleared by FDA, offers expanded clinical applications suitable for oncology, neonatal acute care and the capability of high-throughput (150/hour) and discrete testing.
It uses fluorescent flow cytometry to enumerate nucleated red blood cells (NRBC) from white blood cells, enabling physicians to accurately diagnose anemia and leukemia.
It also discriminates between platelets and fragmented red blood cells in abnormal samples. This can help assure reliable platelet counts with dialysis patients or granulocyte-colony stimulating factor therapy patients. Clearly identifying the different maturity stages of red blood cells also assures accurate assessment of bone marrow activity in patients with anemia and other hematological disorders.
New methods to measure and monitor human progenitor cells during routine CBC testing are in development. Roche Diagnostics
